Inner Mongolia Furui Medical Science Co., Ltd. (SHE:300049)
China
· Delayed Price · Currency is CNY 50.54
-1.43 (-2.75%)
Apr 29, 2026, 3:04 PM CST
SHE:300049 Revenue
In the year 2025, Inner Mongolia Furui Medical Science had annual revenue of 1.60B CNY with 18.26% growth. Inner Mongolia Furui Medical Science had revenue of 494.34M in the quarter ending December 31, 2025, with 33.91% growth.
Revenue
1.60B
Revenue Growth
+18.26%
P/S Ratio
8.63
Revenue / Employee
1.69M
Employees
946
Market Cap
13.77B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.60B | 246.37M | 18.26% |
| Dec 31, 2024 | 1.35B | 195.28M | 16.93% |
| Dec 31, 2023 | 1.15B | 144.97M | 14.37% |
| Jan 1, 2023 | 1.01B | 110.28M | 12.27% |
| Jan 1, 2022 | 898.48M | 90.95M | 11.26% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Anhui Anke Biotechnology (Group) | 2.56B |
| Jinyu Bio-technology | 1.33B |
| Chengzhi | 10.87B |
| InventisBio | 37.29M |
| Staidson (Beijing) BioPharmaceuticals | 244.37M |
| Mabwell (Shanghai) Bioscience | 662.52M |
| Tibet Cheezheng Tibetan Medicine | 2.42B |
| Vcanbio Cell & Gene Engineering Corp., | 1.42B |